Literature DB >> 8821648

Activation patterns of murine B cells after oral administration of an encapsulated soluble antigen.

S L Jain1, K S Barone, M P Flanagan, J G Michael.   

Abstract

Oral administration of soluble protein antigen, ovalbumin (OVA), encapsulated by an acid-resistant acrylic polymer, induced a strong immune response in BDF1 mice. Mice fed the encapsulated OVA showed activation of antigen-specific IgA, IgG and IgG1 isotype antibody-secreting cells which migrated to various lymphoid tissues via the common mucosal immune system traffic pathway. The highest number of antigen-specific antibody secreting cells was found in the Peyer's patches isolated from the upper segment of the small intestine, with their numbers declining along the length of the intestinal tract. Oral administration of this product suggests activation of lymphocytes exhibiting Th2 phenotype as shown by OVA-specific IgA and IgG1 isotype antibody responses. In conclusion, we demonstrated that oral administration of encapsulated soluble protein, in the absence of adjuvant, can activate the murine common mucosal immune system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8821648     DOI: 10.1016/0264-410x(95)00158-w

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women.

Authors:  P A Kozlowski; S Cu-Uvin; M R Neutra; T P Flanigan
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

2.  Inflammation and clearance of Chlamydia trachomatis in enteric and nonenteric mucosae.

Authors:  J U Igietseme; J L Portis; L L Perry
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

3.  Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules.

Authors:  George T Mercier; Pramod N Nehete; Marco F Passeri; Bharti N Nehete; Eric A Weaver; Nancy Smyth Templeton; Kimberly Schluns; Stephanie S Buchl; K Jagannadha Sastry; Michael A Barry
Journal:  Vaccine       Date:  2007-11-05       Impact factor: 3.641

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.